Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea Should Pursue Two-Pronged Strategy In Global Vaccine Hub Bid

Focus On Future Pandemics And NIP

Executive Summary

South Korea is making a strategic push to strengthen its vaccine capabilities, with a focus on COVID-19 and future pandemics and the aim of becoming a global development hub. But one expert told a recent meeting that these goals should not overshadow the government’s original aim of becoming self-sufficient for the national immunization program.

You may also be interested in...



From Antibodies To Vaccines: How Prestige BioPharma Is Shaping Its Future

The vice-chairman of Singapore-based Prestige Group talks to Scrip about the biopharma's strategies in Asia and elsewhere, as it focuses on vaccines for COVID-19 and other diseases, along with novel antibody therapeutics in oncology and biosimilars.

WHO Biomanufacturing Training Hub Plan Offers Korea Chance On World Stage

South Korea welcomes WHO decision to designate the country as a global biomanufacturing training hub, citing various opportunities this could provide in fulfilling its goal of becoming a similar center of worldwide expertise in vaccines.

Korea Policies To Shift To Non-COVID Areas In 2022?

The Pink Sheet takes a look back at major policy developments in South Korea in 2021 and ahead at what’s in store for the coming year.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel